

October 1, 2014



Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland

Conference Expected to Bring Together Executives from Leading MicroCap Companies Within the Global Life Sciences Universe with European Institutional Investors

SOUTH EASTON, Mass., Oct. 1, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: P BIO) ("PBI" or the "Company"), a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced it has been invited to present at the 2nd Global Life Sciences Conference in Warsaw, Poland. The Conference will take place at the Warsaw Stock Exchange on October 2, 2014. Mr. Richard T. Schumacher, President and CEO of PBI, will present a business overview during the Company Sessions, between 8am –11am EDT.

Organized by WDM Capital, Wedbush Europe, and the Warsaw Stock Exchange, participating companies will discuss their innovative technologies, current progress, and future opportunities through corporate presentations and small group meetings. Over 100 leading life sciences institutional investors, fund managers, and analysts from Central and Eastern Europe are expected to participate and assess new investment opportunities.

A live webcast of the conference will be available at:<http://www.lscwarsaw.com>. After the conference, the archived replay will be available at:<http://www.lscwarsaw.com>

Mr. Andrew D. Filipek, Vice Chairman of Wedbush Europe, said: "We are pleased to have Pressure BioSciences present at the 2nd Global Life Sciences Conference in Warsaw. Although only in its second year, the conference is already one of the largest life sciences microcap conferences in Central Europe. The organizers have assembled an impressive list of exciting microcap life sciences companies and an equally impressive group of life sciences investors. We believe many significant investment opportunities will come from this forum."

"PBI's patented pressure cycling technology ("PCT") is an innovative, transformative technology platform that has the potential to significantly improve life sciences research worldwide," commented Mr. Wojciech Gudaszewski, Vice President and Founder of WDM Capital, SA. "The Company has shown impressive technological and operational growth over the past few years. We hope that PBI's first appearance on Polish soil will commence a new chapter in their journey, as we look to find growth opportunities of mutual benefit in Poland."

Mr. Richard T. Schumacher, President and CEO of PBI, said: "We greatly appreciate the

invitation and are excited for the opportunity to present the PBI story to such an impressive group of European investors. It is even more special knowing that the venue is the floor of the Warsaw Stock Exchange, the largest national financial instruments exchange in the region of Central and Eastern Europe and one of the fastest-growing exchanges in all of Europe. We look forward to discussing the potential of PBI and to how we might work with investors and colleagues in Poland to our mutual benefit."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

<http://www.pressurebiosciences.com>

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)

SOURCE Pressure BioSciences, Inc.